BD Diagnostics and Lab21 are to collaborate to develop oncology assays for the BD MAX fully automated bench-top molecular system. Under the terms of the collaboration, Lab21 will develop polymerase chain reaction-based assays on the BD MAX platform for a series of oncology markers, while BD will be responsible for manufacturing and commercialising the tests worldwide.
Epredia was established in July 2019 through the acquisition by PHC Group of the Anatomical Pathology division of Thermo Fisher Scientific. Our name has changed, however as a standalone business our mission remains the same: to improve lives by enhancing cancer diagnostics.
We are powered by the quality brands you know and trust, such as...
10 Union Street, London, SE1 1SZ
2 March, 2026
Online
3-4 March, 2026
Hinxton Hall Conference Centre, Wellcome Genome Campus, Hinxton, CB10 1RQ
9-10 March, 2026
Online
10-11 March, 2026
Henry B. González Convention Center, San Antonio, Texas, USA
21-26 March, 2026
